MarketBeat reported average ratings and TD Cowen reaffirmed a buy rating for Ionis Pharmaceuticals.
1 report, 1 independent
Updated Jun 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported average ratings and TD Cowen reaffirmed a buy rating for Ionis Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
MarketBeat
American personal finance blog
-
TD Cowen
American investment bank
Related events
- Analyst rating updates for Krystal Biotech, including a buy rating from TD Cowen and a consensus rating from MarketBeat.
- Avita Medical received a buy rating reaffirmation from TD Cowen, alongside MarketBeat consensus ratings and SEC insider buying disclosures.
- MarketBeat reported that TD Cowen increased its price objective and gave a buy rating for an unnamed company.
- TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.
- MarketBeat reported on analyst coverage for IONQ, noting that Needham reiterated its buy rating, while Cantor Fitzgerald set a $70.00 price target and reiterated its overweight rating.